- Open Access
Hyperactivation of NF-κB via the MEK signaling is indispensable for the inhibitory effect of cAMP on DNA damage-induced cell death
© Kloster et al; licensee BioMed Central Ltd. 2011
- Received: 14 November 2010
- Accepted: 21 April 2011
- Published: 21 April 2011
With cAMP signaling having a profound inhibitory effect on DNA damage-induced apoptosis in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells, understanding how this signaling pathway affects the survival capacity of the cell has important implications for cancer therapy. We have recently shown that p53 is critical for the inhibitory effect of cAMP on genotoxic agents-mediated apoptosis in BCP-ALLs. Here, we show that elevation of cAMP levels in cells exposed to DNA damage enhances the nuclear translocation and DNA binding of NF-κB by accelerating the phosphorylation of IKKβ and thereby phosphorylation and degradation of IκBα. Furthermore, we show that the ability of cAMP to potentiate the ionizing radiation-induced activation of NF-κB requires the activity of MEK. Importantly, pharmacological or genetic ablation of NF-κB reversed the inhibitory effect of cAMP on DNA damage-induced apoptosis, demonstrating that, in addition to p53, cAMP relies on the activity of NF-κB to provide cells with a survival advantage in the face of DNA damage. Collectively, our results uncover a novel and important interaction between the cAMP and NF-κB pathways that may have implications for the targeted treatment of lymphoid malignancies, such as BCP-ALL, in which aberrant NF-κB activity functions as a driving force for treatment resistance.
- cAMP Signaling
Activation of apoptosis in tumor cells is essential for the ability of cancer therapeutic drugs, such as genotoxic agents, to elicit a successful antineoplastic response [1, 2]. Importantly, the apoptotic process in cancer cells is often compromised, enabling these cells to resist the cytotoxic effect of antitumor drugs and thus leading to the emergence of drug-resistant malignancies [3–5]. The ability of genotoxic agents to induce apoptosis in the target cancer cells is primarily influenced by the activity of two key signaling networks, the nuclear factor-κB (NF-κB) and p53 pathways [6, 7]. NF-κB is a dimeric transcription factor that in the resting state is sequestered in the cytoplasm through its association with one of the inhibitory κB (IκB) proteins . In response to DNA damage, the IκB kinase (IKK) complex phosphorylates IκBα at S32 and S36, an event that marks IκBα for ubiquitination and proteasomal degradation, thus allowing the NF-κB complex (p50/p65) to translocate to nucleus where it binds DNA and regulates the expression of a variety of genes, including antiapoptotic genes [7, 9]. Consistent with this prosurvival function of NF-κB, inhibition of NF-κB activation has been shown to improve the apoptotic response of cells to cancer therapeutics . Furthermore, the constitutive and deregulated activation of NF-κB found in many solid tumors as well as hematological malignancies is believed to promote cell survival and confer treatment resistance [9, 11, 12].
The transcription factor p53 is a tumor suppressor protein that is stabilized and activated in response to various types of cellular stress, including DNA damage [13, 14]. This results in transactivation of a number of downstream genes whose products induce cell cycle arrest or apoptosis depending on the cell type and the nature of stress. For instance, lymphoid cells readily undergo p53-dependent apoptosis in response to DNA damage . The inability to induce p53 or loss of normal p53 function is thought to facilitate cancer initiation and progression and to increase the survival potential of the cell in response to anticancer treatment.
In contrast to most carcinomas, the incidence of p53 mutations in hematological malignancies is notably low [16–18]. This indicates the involvement of other mechanisms that impinge on p53 and prevent its apoptosis-inducing effect. Based on our results in a recent study , we proposed cAMP signaling to be one such mechanism. We showed that activation of cAMP signaling in primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) blasts as well as BCP-ALL-derived cell lines inhibited the accumulation of p53 and protected the cells from DNA damage-induced apoptosis.
Given that the fate of cells exposed to DNA damage depends on the balance between the NF-κB-induced prosurvival signal and the p53-activated proapoptotic program , we wished to investigate whether NF-κB, in addition to p53, plays a role in the ability of cAMP to diminish the apoptotic response of BCP-ALL cells to DNA damage. Here, we show that cAMP potentiates the induction of NF-κB by DNA damage. Furthermore, we show that attenuation of NF-κB activity reverses the inhibitory effect of cAMP on DNA damage-induced apoptosis. Importantly, our results indicate a critical role for MEK signaling in mediating the potentiating effect of cAMP on DNA damage-induced NF-κB activation. Based on these results, we conclude that cAMP, through inhibition of p53 accumulation and simultaneous potentiation of NF-κB activity, renders cells resistant to the apoptosis-inducing effect of DNA damage. Thus, the potential use of NF-κB modulators may prove beneficial in treatment of cancers in which aberrant activation of cAMP signaling endows the cells with a prosurvival advantage.
Alleviation of NF-κB activity reverses the inhibitory effect of cAMP on IR-induced cell death
cAMP enhances IR-induced phoshorylation and degradation of IκBα and subsequent activation of NF-κB
Having identified cAMP as an inducer of IKKβ phosphorylation, we proceeded to examine the effect of cAMP on phosphorylation and degradation of IκBα. To this end, Reh cells were treated with IR in the absence or presence of forskolin, harvested at 2 and 4 h postirradiation and subjected to immunoblot analysis using an anti-phospho-IκBα antibody and an antibody recognizing nonphosphorylated IκBα. In parallel with kinetics of phosphorylation of IKKα and IKKβ, phosphorylation and degradation of IκBα was induced by 2 h after exposure of cells to IR before declining at 4 h postirradiation (Figure 3B). Furthermore, exposure of cells to forskolin potentiated the effect of IR on IκBα phosphorylation and degradation with similar kinetics. Interestingly, although exposure of cells to forskolin alone increased phosphorylation of IKKβ, it failed to induce phosphorylation and degradation of IκBα. The ability of forskolin to potentiate the IR-induced phosphorylation-dependent degradation of IκBα suggested that forskolin would enhance the IR-mediated nuclear accumulation of NF-κB. To examine this notion, Reh cells that were exposed to IR in the absence or presence of forskolin were subjected to subcellular fractionation and the nuclear fraction was analyzed by immunoblotting with antibodies against the p65 subunit of NF-κB. As shown in Figure 3C, in conformity with kinetics of IκBα degradation, the expression of nuclear p65 was induced by 2 h after exposure of cells to IR before declining slightly at 4 h postirradiation. Notably, treatment of cells with forskolin had a marked enhancing effect on the IR-induced nuclear accumulation of p65 at both time points.
Next, we wished to examine whether the enhancing effect of cAMP on IR-mediated activation of NF-κB pathway requires the activity of IKK kinase, the enzyme responsible for phosphorylation of IκBα and thus induction of NF-κB. To this end, we examined the effect of Bay 11-7082 on forskolin-mediated regulation of IR-induced phosphorylation and degradation of IκBα as well as nuclear translocation of p65. Bay 11-7082 is an inhibitor of IKK kinase and attenuates the phosphorylation and subsequent degradation of the NF-κB inhibitor, IκBα. As expected, Bay 11-7082 inhibited the IR-induced phosphorylation and degradation of IκBα, and thus attenuated the translocation of p65 into the nucleus (Figure 3D). Importantly, in cells exposed to IR in the presence of forskolin, Bay 11-7082 inhibited the phosphorylation and degradation of IκBα as well as the nuclear translocation of p65 to levels similar to those found in cells that were treated with only IR in the presence of Bay 11-7082. Thus, the stimulatory effect of cAMP on IR-induced activation of NF-κB pathway depends on IKK kinase activity.
Next, we wished to examine whether cAMP affected the NF-κB-dependent gene transcription. We transiently transfected Reh cells with an NF-κB-dependent luciferase reporter construct and examined them by luciferase assay after exposure to IR in the presence or absence of forskolin. As shown in Figure 4B, the NF-κB luciferase reporter activity was relatively low in untreated cells or cells that were treated with forskolin alone. Exposure of cells to IR increased the NF-κB promoter activity 5 fold within 2 h. The transcriptional activity of NF-κB then decreased gradually so that by 6 h after IR, it was induced 4 fold compared to untreated cells. Notably, pretreatment of cells with forskolin had a profound potentiating effect on the IR-induced NF-κB-dependent transcription at all time points.
Two major downstream targets of cAMP are protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac) [25–27]. To examine whether the enhancing effect of cAMP on NF-κB activity is mediated through PKA or Epac, Reh cells that were transfected with an NF-κB-dependent luciferase reporter construct were exposed to IR in the absence or presence of 8-CPT-cAMP or 8-pCPT-2'-O-Me-cAMP and then examined for NF-κB luciferase reporter activity. 8-CPT-cAMP is an activator of both PKA and Epac, whereas 8-pCPT-2'-O-Me-cAMP is a potent and specific agonist of Epac with no effect on PKA activity . As can be seen in Figure 4C, pretreatment of Reh cells with 8-CPT-cAMP had a robust potentiating effect on IR-induced NF-κB activity. In contrast, exposure of cells to a concentration of 8-pCPT-2'-O-Me-cAMP as high as 400 μM did not enhance the NF-κB transcriptional activity in IR-treated cells, indicating that cAMP potentiates the IR-induced NF-κB activity in a PKA-dependent manner.
Finally, to confirm that the enhancing effect of cAMP on the NF-κB activity also occurs in normal cells, we used splenocytes isolated from 3 × κB-luc transgenic mice , and examined them for luciferase activity after exposure to IR in the absence or presence of forskolin. Similar to the results obtained with Reh cells, treatment of splenocytes with IR led to an increase in luciferase activity within 2 h (Figure 4D). Furthermore, pretreatment of these cells with forskolin significantly enhanced the IR-induced NF-κB activity.
MEK signaling is required for cAMP-mediated activation of NF-κB
To assess the role of MEK signaling in cAMP-mediated enhancement of NF-κB activity following DNA damage, MEK activity in Reh cells that were transfected with an NF-κB-dependent luciferase reporter construct was inhibited by either treatment of cells with PD 98059 or by RNA interference. Cells were then examined by luciferase assay after exposure to IR in the presence or absence of forskolin. As shown in Figure 6B, whereas disruption of MEK signaling with either PD 98059 or MEK1 and MEK2 siRNAs slightly decreased the IR-induced NF-κB promoter activity, it substantially inhibited the potentiating effect of cAMP on IR-mediated NF-κB-dependent transcription.
Finally, to rule out the possibility that the reversal of the inhibitory effect of cAMP on IR-induced cell death through attenuation of MEK1 and MEK2 or NF-κB activities may be due to stabilization of p53, we examined the expression of p53 in cells that were treated with PD 98059 or Bay 11-7082. As shown in Figure 6C, pretreatment of Reh cells with PD 98059 or Bay 11-7082 had no effect on the basal level of p53 protein. The inability of Bay 11-7082 to increase the level of p53 is in contrast with previous studies showing that IKKβ decreases the stability of p53 protein [35, 36]. Furthermore, inhibition of MEK1 and MEK2 or NF-κB did not affect the ability of forskolin to attenuate the IR-mediated accumulation of p53. Collectively, these results indicate that MEK-NF-κB signaling axis plays an important p53-independent role in the inhibitory effect of cAMP on DNA damage-induced cell death.
cAMP induces the expression of survivin in IR-treated cells in an NF-κB-dependent manner
In line with our finding that the cAMP-mediated inhibition of DNA damage-induced cell death depends on the ability of cAMP to hyperactivate NF-κB, during the final phase of the preparation of this manuscript, Safa et al. reported that elevation of cAMP in doxorubicin-exposed Nalm-6 cells induced the activity of NF-κB . Furthermore, these authors showed that NF-κB activity contributes to the ability of cAMP to inhibit cell death in doxorubicin-treated Nalm-6 cells. However, in contrast to our findings showing that elevation of cAMP in DNA-damaged Reh cells induces the expression of survivin without affecting the levels of Bcl-2 or XIAP (for Bcl-2 see ), Safa et al. showed that cAMP increases the expression of Bcl-2 and XIAP in doxorubicin-treated Nalm-6 cells.
Given the importance of NF-κB activity in oncogenesis as well as its contribution to suppression of the apoptotic potential in cancer therapy [9, 12, 40], we also examined the mechanism by which cAMP signaling enhances the DNA damage-induced NF-κB activation. Inactive NF-κB dimers are sequestered in the cytoplasm in association with IκB proteins . Following DNA damage, activated ATM interacts with NEMO in the nucleus and the resulting ATM/NEMO complex translocates to cytoplasm where it activates IKK complex, leading to phosphorylation and subsequent degradation of IκBα . This event facilitates translocation of NF-κB into nucleus where it binds DNA and activates an antiapoptotic transcriptional program. Our observation that forskolin enhances the DNA damage-induced phosphorylation and degradation of IκBα indicated that cAMP positively regulates the IKK complex to induce NF-κB activation. This conclusion was further supported by the finding that inhibition of IKK activity by Bay 11-7082 alleviated the potentiating effect of cAMP on IκBα phosphorylation and degradation. cAMP could enhance the activity of NF-κB by modulating the ATM-NEMO axis. However, the inability of cAMP to affect the DNA damage-induced activation of ATM  suggested that cAMP enhanced NF-κB activity through an alternative mechanism. The finding that abrogation of MEK activity abolishes the ability of cAMP to potentiate the DNA damage-induced activity of NF-κB indicates that MEK signaling functions in such capacity. Importantly, disruption of MEK signaling had no appreciable effect on the activity of NF-κB in cells that were exposed to IR alone. This observation is in contradiction with the results of Panta et al  showing that inhibition of MEK results in downregulation of doxorubicin- or IR-mediated activation of NF-κB. Whereas the cells utilized by Panta et al were mainly of fibroblast origin, we have exclusively used cells of B lymphocyte lineage. Therefore, this discrepancy may be explained by the suggestion that the MEK pathway relays the DNA damage signal to NF-κB in a cell type-specific manner. Notwithstanding, our results show that, at least in BCP-ALL and lymphoblastoid cells, the MEK signaling engages the NF-κB pathway in DNA damaged cells only when cAMP signaling is activated.
The mechanism by which cAMP activates MEK signaling should also be addressed. It can be envisioned that stimulation of MEK phosphorylation and activation by cAMP can be achieved by (i) direct phosphorylation of MEK by PKA, or (ii) positive regulation of an activating event upstream of MEK proteins. The finding that MEK is not efficiently phosphorylated by PKA in vitro diminishes the possibility that in vivo PKA activates MEK through direct phosphorylation. At present, we favor the second possibility in which cAMP induces the activity of a factor that is required for phosphorylation and activation of MEK. This mechanism is supported by the findings that cAMP stimulates MEK activity though activation of B-RAF pathway .
Degradation of IκBα and the resulting nuclear translocation of NF-κB and its binding to DNA are necessary but insufficient events for the induction of an NF-κB response. Covalent modifications of key residues of NF-κB are also crucial for its transcriptional activity downstream of IκBα . Furthermore, these modifications are thought to determine the strength and duration of the NF-κB transcriptional response. For instance, inducible phosphorylation of p65 on S276 by PKA has been shown to promote its interaction with transcriptional coactivators p300 and CBP and thus enable NF-κB to activate gene transcription [44–46]. In the absence of antibodies specific for phosphorylated p65 on S276 , we can only speculate that elevation of cAMP in cells exposed to DNA-damaging agents most probably leads to phosphorylation of p65 on S276, thus enhancing the DNA damage-induced transcriptional activity of NF-κB. In such case, cAMP signaling would positively affect the activity of NF-κB at two levels: one involves enhancement of DNA damage-induced phosphorylation and degradation of IκBα, an event that positively regulates nuclear translocation of NF-κB. At the second level, cAMP, by amplifying the PKA-dependent phosphorylation of p65, stimulates the transcriptional activity of NF-κB.
Alterations in NF-κB activity is recognized as key pathological feature in various lymphoid malignancies . Indeed, aberrant activity of NF-κB occurs in nearly all childhood ALL tumors , an event suggested to contribute to resistance of these cells to DNA damage. The credentials of cAMP as an antiapoptotic factor in BCP-ALL cells  and its ability to hyperactivate NF-κB lend further support to our notion that inhibitors of cAMP signaling pathway might prove beneficial in treatment of BCP-ALL tumors.
Reagents and antibodies
Forskolin and propidium iodide (PI) were obtained from Sigma-Aldrich. PD 98059 was purchased from Tocris Bioscience. Bay 11-7082 was obtained from Calbiochem. 8-CPT-cAMP and 8-pCPT-2'-O-Me-cAMP were from BioLog. Luciferase Assay system was from Promega. Antibodies against IκBα (#9242), phospho-IκBα (S32; #2859), p65 (#3034), IKKα (#2682), IKKβ (#2684), phospho-IKKα/β (S176/S180; #2697), ERK1/2 (#9102), and phosphor-ERK1/2 (T202/Y204; #9101) were from Cell Signaling Technology. Anti-actin (H196) and anti-Lamin B1 (H-90) were obtained from Santa Cruz Biotechnology.
Cell cultures, radiation treatment and cell death analysis
Reh , EU-3 and TK6 were cultured as previously described . For isolation of mice splenocytes, mice were sacrificed by cervical dislocation and spleens were removed and homogenized in a petri dish. Splenocytes were washed and adjusted to 2 × 106 cells/ml in RPMI supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies), 2 mM glutamine, 125 U/ml penicillin, 125 μg/ml streptomycin (Gibco), and 50 μM β-mercaptoethanol (Sigma-Aldrich) at 37 °C in a humified incubator with 5% CO2. For treatment of cells with γ-radiation, cells were exposed to a 137Cs source at a dose rate of 4.3 Gy/min using a Gammacell irradiator from MSD Nordion. To analyze cell death, cells were incubated with PI (20 μg/ml) at room temperature for 10 min before examination for PI uptake by flow cytometry.
Transfection and reporter gene assay
For siRNA transfection, Reh or TK6 cells (6 × 106) were transfected with 16 pmol Signalsilence NF-κB p65 siRNA (6261; Cell signaling Technology) or stealth RNAi for human MEK1 and MEK2 (12935-025; Invitrogen) using the nucleofection solution R and the O-17 program (Reh) or solution V and the X-05 program (TK6) with a nucleofector device (Amaxa Biosciences). SignalSilence Control siRNA (6201; Cell Signaling technology) or control siRNA (12935-300; invitrogen) were used as controls for p65 and MEK1/2 siRNAs, respectively. Cells were then incubated for 24 h before further treatment. For reporter gene assay, Reh cells were cotransfected with 8 μg κB-luciferase plasmid and 4 μg β-galactosidase expression vector. 20 h after transfection, cells were subjected to further treatment. To prepare lysates, 100 μl reporter lysis buffer (Promega) was added to each sample, and the supernatant was collected after centrifugation at 13,000 rpm for 2 min. Aliquots of cell lysates (20 μl) containing equal amounts of protein (20-30 μg) were placed into wells of an opaque black 96-well microplate. An equal volume of luciferase substrate was added to all samples, and luminescence was measured in a microplate luminometer. The value of luciferase activity was normalized to transfection efficiency monitored by the co-transfected β-galactosidase expression vector.
NF-κB DNA Binding Assays
Nuclear protein binding to a consensus NF-κB oligonucleotide was determined using an enzyme-linked immunosorbent assay-based kit (TransAm p65, Active Motif). Absorbance was read at 450 nm.
Reh cells were resuspended in buffer A (10 mM Tris-HCl [pH 7.5], 10 mM NaCl, 3 mM MgCl2, 0.1 mM PMSF, 1 mM DTT. NP-40 (0.05%) was added, and the cells were incubated for 20 min on ice. The lysates were centrifuged for 5 min at 200 × g at 4 °C, and the supernatant collected (cytosolic fraction). The nuclear fraction was obtained by sonication of the pellet in buffer A.
For immunoblot analysis, cells were lysed in radioimmunoprecipitation buffer (RIPA; 50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% NP-40, 50 mM NaF, 10 mM β-glycerophosphate, 0.1% SDS, 0.5% EDTA, 1 mM Na3VO4, 0.2 mM PMSF, 10 μg/ml leupeptin, 0.5% aprotinin). Equal amounts of protein were separated on a 7.5% (for IKKα/β) and 10% (for other proteins) SDS-PAGE. After transfer to a nitrocellulose membrane (GE Healthcare), proteins were detected using appropriate primary antibodies and the enhanced chemiluminescence detection system (ECL Plus, Amersham Biosciences).
SPSS 14.0.2 for Windows was used to perform statistical analysis. The paired sample t test was used to test significance in cell line experiments, whereas the Wilcoxon signed-rank test was applied to experiments with mice splenocytes. Specific cell death was calculated using the following equation: (% experimental cell death in the ionizing (IR)-treated sample - % spontaneous cell death in the absence of IR)/(100% - % spontaneous cell death in the absence of IR) × 100. In all figures, histograms show mean values of the indicated number of experiments with error bars corresponding to SEM values.
This work was supported by The University of Oslo, The Norwegian Cancer Society, Blix Foundation and The Jahre Foundation.
We thank Camilla Solberg for excellent technical assistance. We gratefully acknowledge Dr. Rune Blomhoff for kindly providing the 3 × κB-luc transgenic mice.
- Green DR, Evan GI: A matter of life and death. Cancer Cell. 2002, 1: 19-30. 10.1016/S1535-6108(02)00024-7View ArticlePubMedGoogle Scholar
- Schmitt CA, Lowe SW: Apoptosis and therapy. J Pathol. 1999, 187: 127-137. 10.1002/(SICI)1096-9896(199901)187:1<127::AID-PATH251>3.0.CO;2-TView ArticlePubMedGoogle Scholar
- Persidis A: Cancer multidrug resistance. Nat Biotechnol. 1999, 17: 94-95. 10.1038/5289View ArticlePubMedGoogle Scholar
- Igney FH, Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002, 2: 277-288. 10.1038/nrc776View ArticlePubMedGoogle Scholar
- Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002, 108: 153-164. 10.1016/S0092-8674(02)00625-6View ArticlePubMedGoogle Scholar
- Vousden KH: Activation of the p53 tumor suppressor protein. Biochim Biophys Acta. 2002, 1602: 47-59.PubMedGoogle Scholar
- Janssens S, Tschopp J: Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ. 2006, 13: 773-784. 10.1038/sj.cdd.4401843View ArticlePubMedGoogle Scholar
- Hayden MS, Ghosh S: Shared principles in NF-kappaB signaling. Cell. 2008, 132: 344-362. 10.1016/j.cell.2008.01.020View ArticlePubMedGoogle Scholar
- Basseres DS, Baldwin AS: Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006, 25: 6817-6830. 10.1038/sj.onc.1209942View ArticlePubMedGoogle Scholar
- Kim HJ, Hawke N, Baldwin AS: NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006, 13: 738-747. 10.1038/sj.cdd.4401877View ArticlePubMedGoogle Scholar
- Nakanishi C, Toi M: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005, 5: 297-309. 10.1038/nrc1588View ArticlePubMedGoogle Scholar
- Packham G: The role of NF-kappaB in lymphoid malignancies. Br J Haematol. 2008, 143: 3-15. 10.1111/j.1365-2141.2008.07284.xView ArticlePubMedGoogle Scholar
- Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 2007, 8: 275-283. 10.1038/nrm2147View ArticlePubMedGoogle Scholar
- Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408: 307-310. 10.1038/35042675View ArticlePubMedGoogle Scholar
- Pettitt AR, Sherrington PD, Stewart G, Cowley JC, Taylor AM, Stankovic T: p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001, 98: 814-822. 10.1182/blood.V98.3.814View ArticlePubMedGoogle Scholar
- Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia. 1992, 6: 42-46.PubMedGoogle Scholar
- Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, Miller CW, Ludwig L, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP: Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood. 1993, 82: 3163-3169.PubMedGoogle Scholar
- Peller S, Rotter V: TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 2003, 21: 277-284. 10.1002/humu.10190View ArticlePubMedGoogle Scholar
- Naderi EH, Findley HW, Ruud E, Blomhoff HK, Naderi S: Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood. 2009, 114: 608-618. 10.1182/blood-2009-02-204883View ArticlePubMedGoogle Scholar
- DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M: A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 1997, 388: 548-554. 10.1038/41493View ArticlePubMedGoogle Scholar
- Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A: IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997, 278: 860-866. 10.1126/science.278.5339.860View ArticlePubMedGoogle Scholar
- Delhase M, Hayakawa M, Chen Y, Karin M: Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science. 1999, 284: 309-313. 10.1126/science.284.5412.309View ArticlePubMedGoogle Scholar
- Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999, 18: 6853-6866. 10.1038/sj.onc.1203239View ArticlePubMedGoogle Scholar
- Burstein E, Duckett CS: Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol. 2003, 15: 732-737. 10.1016/j.ceb.2003.10.005View ArticlePubMedGoogle Scholar
- Walsh DA, Perkins JP, Krebs EG: An adenosine 3', 5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. J Biol Chem. 1968, 243: 3763-3765.PubMedGoogle Scholar
- de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL: Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature. 1998, 396: 474-477. 10.1038/24884View ArticlePubMedGoogle Scholar
- Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM: A family of cAMP-binding proteins that directly activate Rap1. Science. 1998, 282: 2275-2279.View ArticlePubMedGoogle Scholar
- Enserink JM, Christensen AE, de Rooij J, van Triest M, Schwede F, Genieser HG, Døskeland SO, Blank JL, Bos JL: A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol. 2002, 4: 901-906. 10.1038/ncb874View ArticlePubMedGoogle Scholar
- Carlsen H, Moskaug JO, Fromm SH, Blomhoff R: In vivo imaging of NF-kappa B activity. J Immunol. 2002, 168: 1441-1446.View ArticlePubMedGoogle Scholar
- Arsura M, Mercurio F, Oliver AL, Thorgeirsson SS, Sonenshein GE: Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol. 2000, 20: 5381-5391. 10.1128/MCB.20.15.5381-5391.2000PubMed CentralView ArticlePubMedGoogle Scholar
- Ryan KM, Ernst MK, Rice NR, Vousden KH: Role of NF-kappaB in p53-mediated programmed cell death. Nature. 2000, 404: 892-897. 10.1038/35009130View ArticlePubMedGoogle Scholar
- Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW, Ingram AJ: ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem. 2002, 277: 12710-12717. 10.1074/jbc.M111598200View ArticlePubMedGoogle Scholar
- Panta GR, Kaur S, Cavin LG, Cortés ML, Mercurio F, Lothstein L, Sweatman TW, Israel M, Arsura M: ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol. 2004, 24: 1823-1835. 10.1128/MCB.24.5.1823-1835.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Shaul YD, Seger R: The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007, 1773: 1213-1226. 10.1016/j.bbamcr.2006.10.005View ArticlePubMedGoogle Scholar
- Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM: Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci USA. 2009, 106: 2629-2634. 10.1073/pnas.0812256106PubMed CentralView ArticlePubMedGoogle Scholar
- Yang PM, Huang WC, Lin YC, Huang WY, Wu HA, Chen WL, Chang YF, Chou CW, Tzeng CC, Chen YL, Chen CC: Loss of IKKbeta activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis. J Cell Mol Med. 2010, 14: 687-698.PubMed CentralView ArticlePubMedGoogle Scholar
- Baud V, Karin M: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009, 8: 33-40. 10.1038/nrd2781PubMed CentralView ArticlePubMedGoogle Scholar
- Altieri DC: New wirings in the survivin networks. Oncogene. 2008, 27: 6276-6284. 10.1038/onc.2008.303PubMed CentralView ArticlePubMedGoogle Scholar
- Safa M, Zand H, Mousavizadeh K, Kazemi A, Bakhshayesh M, Hayat P: Elevation of cyclic AMP causes an imbalance between NF-kappaB and p53 in NALM-6 cells treated by doxorubicin. FEBS Lett. 2010, 584: 3492-3498. 10.1016/j.febslet.2010.07.009View ArticlePubMedGoogle Scholar
- Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest. 2001, 107: 241-246. 10.1172/JCI11991PubMed CentralView ArticlePubMedGoogle Scholar
- Ramstad C, Sundvold V, Johansen HK, Lea T: cAMP-dependent protein kinase (PKA) inhibits T cell activation by phosphorylating ser-43 of raf-1 in the MAPK/ERK pathway. Cell Signal. 2000, 12: 557-563. 10.1016/S0898-6568(00)00097-8View ArticlePubMedGoogle Scholar
- Dumaz N, Marais R: Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J. 2005, 272: 3491-3504. 10.1111/j.1742-4658.2005.04763.xView ArticlePubMedGoogle Scholar
- Chen LF, Greene WC: Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol. 2004, 5: 392-401. 10.1038/nrm1368View ArticlePubMedGoogle Scholar
- Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S: The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell. 1997, 89: 413-424. 10.1016/S0092-8674(00)80222-6View ArticlePubMedGoogle Scholar
- Zhong H, Voll RE, Ghosh S: Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell. 1998, 1: 661-671. 10.1016/S1097-2765(00)80066-0View ArticlePubMedGoogle Scholar
- Zhong H, May MJ, Jimi E, Ghosh S: The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell. 2002, 9: 625-636. 10.1016/S1097-2765(02)00477-XView ArticlePubMedGoogle Scholar
- Spooren A, Kolmus K, Vermeulen L, Van Wesemael K, Haegeman G, Gerlo S: Hunting for serine 276-phosphorylated p65. J Biomed Biotechnol. 2010, 2010: 275892-PubMed CentralView ArticlePubMedGoogle Scholar
- Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C: Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000, 14: 399-402. 10.1038/sj.leu.2401705View ArticlePubMedGoogle Scholar
- Rosenfeld C, Goutner A, Venuat AM, Choquet C, Pico JL, Dore JF, Liabeuf A, Durandy A, Desgrange C, De The G: An effect human leukaemic cell line: Reh. Eur J Cancer. 1977, 13: 377-379.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.